prophylactic intranasal administration of a tlr2 agonist increased upper respiratory tract viral shedding in a sars-cov-2 challenge ferret model
prophylactic intranasal administration of a tlr2 agonist increased upper respiratory tract viral shedding in a sars-cov-2 challenge ferret model
there was one ferret in group 1 showing detectable, but below the quantifiable limit, viral rna, and no other inna-051 treated ferrets showing detectable viral rna in lung tissue on day 3 and days 12-14 dpc this study provides evidence supporting a novel approach to prevent sars-cov-2 transmission, based on reduced viral shedding, following prophylactic i.n administration of inna-051.", "we show that prophylactic intra-nasal administration of the tlr2/6 agonist inna-051 in a sars-cov-2 ferret infection model effectively reduces levels of viral rna in the nose and throat."


































)